Dr. Ashley Brenton is the Vice President of Real World Evidence and Genomics for Optum Life Sciences. In this role, she is responsible for leading data strategy, product development, business development and operations for genomics. Ashley bridges the gap between clinical genomics and product development to leverage the wealth of Optum data into commercial datasets and stategic alliances to drive precision medicine initiatives. Prior to joining Optum, Dr. Brenton was the Chief Science Officer at Mycroft Bioanalytics, where she led corporate valuation and sales strategy of the intellectual property portfolio, including the worlds largest Clinicogenomic biobank in chronic pain. Previously, Dr. Brenton developed and commercialized a number of precision medicine tests and algorithms while building Clinicogenomic datasets. Ashley is an accomplished athlete, completing the Ironman twice and a number of ultramarathons, and competing in CrossFit competitions. She lives in Washington state with her husband and two daughters.
- Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.